Case Series

Screening Children with a Family History of Central Congenital Hypoventilation Syndrome

Hina Emanuel, Kimberly Rennie, Kelly Macdonald, Aravind Yadav, and Ricardo A. Mosquera

1Department of Pediatrics, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA
2University of Houston, Texas Institute for Measurement, Evaluation, and Statistics, Department of Psychology, Houston, TX, USA

Correspondence should be addressed to Ricardo A. Mosquera; ricardo.a.mosquera@uth.tmc.edu

Received 4 October 2019; Accepted 25 February 2020; Published 26 March 2020

Copyright © 2020 Hina Emanuel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Congenital central hypoventilation syndrome (CCHS) is a rare genetic disorder of an autonomic nervous disorder that affects breathing. It is characterized by respiratory insufficiency secondary to insensitivity to hypoxemia and hypercarbia, particularly during sleep leading to persistent apnea. We report four individuals across two generations harboring heterozygous polyalanine repeat mutations (PARMs) in PHOX2B with a varying degree of phenotypic clinical manifestations. Two family members who reported to be “asymptomatic” were subsequently diagnosed with CCHS, based on genetic testing, obtained because of their family history. Genetic studies in the family including a mother and three offsprings revealed in-frame five amino acid PARMs of PHOX2B consistent with CCHS in addition to full clinical assessment. All affected individuals had evidence of hypercapnia on blood gas analysis with PCO₂ in the range of 32–70 (mean; 61). Nocturnal polysomnogram revealed evidence of hypoventilation in two individuals (1 offspring and mother) with the end-tidal CO₂ median of 54. Magnetic resonance imaging of brain revealed no abnormalities in the brain stem. There was no evidence of cor pulmonale on echocardiograms in all individuals. Neuro-psychological testing was conducted on all four patients; two patients (mother and 1 offspring) had normal results, while the other two offspring exhibited some impairments on neuropsychological testing. This case series emphasizes the importance of screening first-degree relatives of individuals with confirmed CCHS to minimize complications associated with long-term ventilatory impairment. It also suggests that some patients with CCHS should undergo neuropsychological evaluations to assess for cognitive weaknesses secondary to their CCHS.

1. Introduction

Congenital central hypoventilation syndrome (CCHS) is also known as Ondine’s curse and is an autosomal dominant disease with an estimated incidence of one per 200,000 live births. CCHS is characterized by respiratory insufficiency, dysregulation of ventilatory hemostasis during nonrapid eye movement (NREM) leading to alveolar hypoventilation, and arterial hypoxemia in settings of normal lung mechanics. CCHS is diagnosed in the absence of primary neuromuscular, metabolic, infectious, pulmonary, or cardiac diseases or brainstem lesion [1]. The disease-defining gene for CCHS is the paired-like homeobox 2B gene (PHOX2B). Mutations in PHOX2B are responsible for CCHS. Polyalanine repeat mutations (PARMs) in PHOX2B account for more than 90% of CCHS cases. The majority of PARMs are considered to arise de novo, and about 10% of the mutations are inherited mostly from asymptomatic parents with somatic mosaicism and rarely from affected parents [2,3].

We present the case of a family with a mother and three offsprings from different biological fathers with identical polyalanine repeat mutations of PHOX2B with varying degree of penetrance, expressivity, and, henceforth, clinical manifestations. We highlight discord in phenotypic and
genotypic expression among the family of a mother and three offsprings and importance of screening first-degree relatives to identify CCHS in individuals with no overt symptoms.

2. Methods

The identification of CCHS in a family of two siblings prompted evaluation of the rest of the family members for CCHS. We performed genetic testing to confirm diagnosis of CCHS in all family members. Individuals with confirmed genetic testing for CCHS underwent complete clinical assessment. Complete clinical assessment included overnight polysomnogram using standard protocol in the mother and two siblings, neuropsychological evaluation using valid standardized scales which was conducted by a licensed neuropsychologist, and a cardiological assessment by using an electrocardiograph and echocardiograph.

All individuals (n=4; age: range, 1–31 years) had PHOX2B sequence analysis carried out, which showed heterozygous p. Ala241 (25) polyalanine repeats, the Epworth Sleepiness Scale (ESS) score between 4 and 5, normal brain MRI, echocardiogram with no cor pulmonale, and full-scale intelligence quotient (FSIQ) and showed average intellectual functioning for proband’s brother (106) and proband’s mother (94), significant impairment in cognitive, language, and motor development (70) for proband’s sister, below average intellectual functioning (83) for proband’s mother (94), significant impairment in average intellectual functioning for proband’s brother (106) and full-scale intelligence quotient (FSIQ) which confirmed the diagnosis of CCHS (Table 1). A tracheostomy tube was placed for long-term ventilatory support. He was eventually weaned to room air during a day at one year of age. PHOX2B analysis was performed at 10 years of age for screening in settings of the family history criteria for a diagnosis of attention deficit hyperactivity disorder (Table 1).

The proband’s 12-month-old maternal half-sister was born at 40 weeks of gestation via normal vaginal delivery. She was discharged home on room air 2 days after birth. She was readmitted with multiple episodes of apnea and respiratory failure with hypoxemia and hypercapnia at seven days of life requiring invasive ventilation and eventually tracheostomy placement for long-term ventilatory support. Infectious, cardiological, neurological, and primary pulmonary etiologies were ruled out. No pathological rhythm abnormalities were identified on the electrocardiogram. NPSG was not performed at the time of diagnosis although blood gases showed hypercapnia; PCO₂ max 70 (Table 1, Figure 1). Echocardiography showed normal heart structures (Table 1). MRI revealed no intracranial or brain stem pathology. Due to high degree of clinical suspicion of CCHS in settings of siblings with CCHS, PHOX2B genetic analysis was sent. PHOX2B sequence analysis revealed heterozygous p. Ala241(25) polyalanine repeats which confirmed diagnosis of CCHS (Table 1). Neuropsychological testing for this patient indicated significant impairment in her cognitive, language, and motor development (Table 1). Screening for socioemotional and behavioral disorders was negative.

The case of two siblings with CCHS prompted screening of other family members, which included the mother and the 10-year-old brother. In addition to routine screening as part of standard care of CCHS, we included clinical assessment to inquire about the symptoms of CO₂ narcosis, autonomic dysregulation, day-time sleepiness, anxiety, and depression. There was no evidence of clinical manifestations of autonomic dysregulation in other family members. The proband’s 10-year-old full brother was born at 36 weeks of gestation via normal vaginal delivery with a medical history significant for episodes of apnea in settings of respiratory syncytial virus but otherwise have been unremarkable from pulmonary standpoint. PHOX2B analysis was performed at 10 years of age for screening in settings of the family history of CCHS. PHOX2B sequence analysis showed identical PHOX2B mutation 25 polyalanine repeats (Table 1). Blood gas showed a PCO₂ of 58 (Table 1, Figure 1). NPSG revealed an apneic hypopnea index (AHI) of 4.9/hr, obstructive AHI of 3.4/hr, central AHI of 0.2/hr, and REM supine AHI of 0.2/hr (Table 1). End-tidal CO₂ averaged 56 during NREM sleep, with a maximum value of 66, and remained above 50, 79% of total sleep time (TST). Average oxygen saturation remained 94% during TST (Table 1). ESS was reported as 4/24 (Table 1). The echocardiogram showed small PDA, trivial pulmonary, and tricuspid regurgitation with no right ventricular strain. No pathological rhythm variants on the electrocardiogram were identified. MRI of the brain revealed no evidence of brain stem disorders. No ophthalmological, neurological, or gastrointestinal problems were observed. Neuropsychological testing indicated intact intellectual
testing indicated intact intellectual functioning (Table 1).

Results of the mother’s neuropsychological and behavioral functioning were identified (Table 1). She reported early morning headaches and fatigue (Table 1, Figure 1). Nocturnal polysomnogram showed a total sleep efficiency of 87% with a TST of 400 mins, AHI 5/24 (Table 1). She reported early morning headaches and fatigue (Table 1). Nocturnal polysomnogram showed a total sleep efficiency of 87% with a TST of 400 mins, AHI 5/24 (Table 1). She reported early morning headaches and fatigue (Table 1).

### 4. Discussion

This family demonstrates a novel PHOX2B p. Ala24.1(25) gene in four individuals across two generations with highly variable penetrance ranging from respiratory failure during the neonatal period to later age with hypoventilation while asleep. Our study emphasizes the importance of screening of parents and at-risk siblings with subtle clinical findings through genetic analysis to identify PHOX2B pathogenic variant. In addition, given the rarity of disease, varied clinical manifestation, and lack of experience of medical professionals as evidenced by the previous literature, this study seeks to increase awareness of CCHS diagnosis, clinical manifestation, and long-term outcomes [4,5]. Through incorporation of questions pertaining to sleep, neurocognitive functioning, and general well-being, this study highlights the importance of comprehensive evaluation of CCHS including NPSG, evaluation of breathing while awake, echocardiogram, Holter monitoring and screening for neurocristopathies, and neuropsychological evaluation. Our case study highlights the importance of screening of at-risk asymptomatic family members through screening questions and a pertinent medical history followed by genetic testing. Genetic testing should not be limited to parents alone but should be extended to all family members at risk for CCHS. Had it not been for screening, the proband’s 10-year-old brother and the mother would have remained undetected.

A mutation in the PHOX2B gene is a requisite to diagnosis of CCHS. PHOX2B is involved in the regulation of the autonomic nervous system and respiratory control neurons. The majority (>90%) of PHOX2B mutations are heterozygous for an in-frame triplet duplication PARMs with the resultant genotype of 24–33 alanine repeats [6]. The CCHS phenotype has not been associated with any degree of somatic mosaicism so far, suggesting a germline origin for most PARMs in affected CCHS patients, which is consistent with our case series. De novo PHOX2B pathogenic variant accounts for most of the cases of CCHS with remaining cases of CCHS transmitted from affected parents with some degree of mosaicism, germline or somatic in PHOX2B variant with 50%, or a lower chance of acquiring pathogenic variant. The presence of the same PHOX2B mutation in parent-offspring supports an autosomal mode of inheritance. Our case series presents the identical PHOX2B mutation with varying degrees of penetrance and the time of onset which could be secondary to gene modifiers [7,8].
The evaluation of parents, children, and at-risks siblings of individuals with CCHS depends on the pathogenic variant identified in the proband. Our study emphasizes the importance of screening first-degree relatives of an individual in a stepwise approach [9–11], prenatal testing, and genetic counseling to make informed medical and personal decisions. The PHOX2B screening test (fragment analysis) is performed if child has PARM or frame shift NPARM. PHOX2B mutation confirmed CCHS. If no mutation is identified, no further testing is advised; however, germline mosaicism cannot be ruled out. If the PHOX2B pathogenic variant is identified, there is a risk of transmitting mutation in pregnancy and warrants prenatal testing as the risk to the sibs is 50% if the proband’s parent is affected, risk is 50% or lower if the proband’s affected parent has mosaicism for the PHOX2 pathogenic variant, and even if the proband’s parents are unaffected, there still remains risk to the proband’s siblings due to mosaicism. Once the pathogenic variant is identified, genetic counseling can be offered to individuals at risk for CCHS to make informed decisions, prenatal testing, and preimplantation genetic diagnosis and to discuss future outcomes for themselves and offsprings before pregnancy. Results of our neuropsychological testing suggest that cognitive deficits may be associated with medical severity of CCHS. Routine neuropsychological testing may be warranted, especially for patients with more severe forms of the disease.

In conclusion, this case series highlights the importance of screening at-risk family members of an individual with CCHS; so genetic counseling can be offered to at-risk individuals in regard to long-term health implications of CCHS. This case report emphasizes the need of validated tools to screen for specific sleep, neurocognitive, and general well-being questions pertaining to CCHS in family members of the affected individual. Further research is needed to provide insight into applicability and outcomes of screening tools in clinical practice. With early diagnosis and careful ventilatory management, the sequelae of hypoxia and morbidity should be minimized and long-term outcome improved.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References


